Home

Acute kidney injury (AKI) is a common clinical syndrome associated with high mortality, increased morbidity and increased risk of chronic kidney disease. Strategies to reduce the mortality of patients with AKI, beyond renal replacement therapies as supportive care, have not generally been effective. Nevertheless, novel interventions, devices, and compounds developed by academia and the pharmaceutical industry hold promise.

The benefits and side-effects of newly developed therapies need to be tested in smaller diverse patient groups before definitive large-scale multi-center randomized controlled trials can be initiated. A number of unresolved clinical trial design issues need to be addressed to ameliorate this important clinical problem.

This workshop will address design of clinical trials for acute kidney injury, and will highlight novel interventions and therapeutic agents.

For questions concerning program content, contact:

Paul L. Kimmel, M.D., F.A.C.P., F.A.S.N.
Senior Advisor
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Phone:  (301) 594-1409
E-mail:  kimmelp@extra.niddk.nih.gov

Yining Xie, M.D.
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Phone:  (301) 594-7713
Email:  yining.xie@nih.gov

For questions concerning logistical information or registration, contact:

Michelle Watson
The Scientific Consulting Group, Inc.
Phone:  (301) 670-4990
Email:  mwatson@scgcorp.com